|
|
|
|
|
|
|
|
|
|
|
|
|
12.12.25 - 13:42
|
XFRA: BO1: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
BIOCRYST PHARMAC. DL-,01 BO1 US09058V1035
AB/FROM ONWARDS 12.12.2025 13:32 CET...
|
|
|
|
|
12.12.25 - 13:01
|
XFRA: BO1: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
BIOCRYST PHARMAC. DL-,01 BO1 US09058V1035 BAW/UFN...
|
|
|
|
|
04.12.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.11.25 - 14:06
|
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
|
|
|
-- BioCryst's Acquisition of Astria Expected to Close in the First Quarter of 2026 --
-- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial --
-- Final Phase 1b/2 ALPHA-STAR Results in 29 HAE Patients Reinforces Navenibart's Robust HAE Attack Prevention and Favorable Safety Profile --
-- STAR-0310, an OX40 Antagonist, Demonstrated a Best-In-Class Profile with Initial Phase 1a Data Presented at the European Academy of Dermatology and Venereology Congress --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
“We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people ...
|
|
|
05.11.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
